Precautions for taking osimertinib: interstitial lung disease, QT interval prolongation, and cardiac toxicity
Osimertinib is an oral third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI).
1. Management of interstitial lung disease (ILD)
Identifying symptoms: newly developed or worsening respiratory distress, dry cough, fever, or hypoxemia.
Urgent handling: In case of suspected ILD, Osimertinib should be immediately suspended and comprehensive diagnostic evaluation (high-resolution CT, etc.) should be initiated.
Grading strategy:
Diagnosed with ILD: permanent discontinuation of osimertinib is required, and treatment with corticosteroids and other medications should be given according to the condition.
High risk reminder: For patients with a history of ILD or concomitant lung diseases, imaging monitoring should be strengthened during medication.
2. QT interval prolongation and arrhythmia
Monitoring requirements: Regular re examination of electrocardiogram (ECG) and electrolytes (especially blood potassium and magnesium) before and during treatment.
Risk overlay: When combining the use of other drugs known to prolong the QT interval (such as certain antiarrhythmic drugs, antibiotics), it is necessary to increase monitoring frequency.
Critical value handling: If the QTc interval is significantly prolonged (usually>500ms) or symptoms such as fainting and palpitations occur, medication should be suspended and electrolyte imbalances corrected.
Permanent discontinuation indication: When QTc interval is prolonged and accompanied by apical torsion transition ventricular tachycardia or polymorphic ventricular tachycardia, permanent discontinuation is required.
3. Cardiotoxicity (heart failure and cardiomyopathy)
Symptom monitoring: Pay attention to newly developed or worsening symptoms of heart failure such as shortness of breath, sitting breathing, lower limb edema, and nighttime waking up.
Functional evaluation: When the left ventricular ejection fraction (LVEF) is below 50% or significantly decreases from baseline, Axitinib should be temporarily discontinued.
Optimization management: After the suspension, joint efforts should be made with the cardiology department to optimize the treatment of heart failure; If LVEF cannot recover or symptoms persist, permanent discontinuation of medication should be considered.
4. Combination medication and baseline assessment
Baseline screening: For those with a history of heart disease (myocardial infarction, heart failure, arrhythmia), a consultation with a cardiologist is required before medication.
Avoid combination: Avoid using strong CYP3A4 inducers or inhibitors in combination to avoid affecting the blood concentration of osimertinib and indirectly increasing the burden on the heart.
Disclaimer：《Precautions for taking osimertinib: interstitial lung disease, QT interval prolongation, and cardiac toxicity》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！